We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...

Sanofi SAN 1.00% agreed to buy Blueprint Medicines BPMC -0.15% for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in ...

As per Sanofi’s statement, the deal involves a cash payment of USD129 per share, representing a roughly 27 percent premium over Blueprint’s most recent closing stock price of USD101.35.

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck ...

The French pharmaceutical giant struck a deal to buy the Cambridge biotech for about $9.1 billion, or $129 per share. Blueprint’s (Nasdaq: BPMC) shares began trading at $103.17 apiece on Monday ...

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi SAN-1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Investing.com -- Shares of Blueprint Medicines Corp (NASDAQ: BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (EPA: SASY) (NASDAQ: SNY) in a ...

The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.